Cardiovascular Risks with Azithromycin and Other Antibacterial Drugs

The FDA recently approved labeling changes advising against the use of azithromycin in patients with known cardiovascular risk factors such as QT-interval prolongation, hypokalemia, hypomagnesemia, bradycardia, or use of class IA or class III antiarrhythmic agents.